Sagimet Biosciences Inc.
Sagimet Biosciences Inc. (SGMT): 3 pipeline candidates · ~36 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
35.6 months
N/A
Lead: Phase 2
3 candidates
N/A
0 buys · 4 sells (180d)
A transparent, data-derived signal for Sagimet Biosciences Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$403.2M
Cash
$36.6M
Quarterly Burn
$8.6M
Runway
35.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| denifanstat | Phase 1 |
| tvb-2640 | Phase 2 |
| tvb-3567 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
86
Total value held
$71.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,197,838 | $11.5M |
| marshall wace, llp | 966,253 | $5.0M |
| baker bros. advisors lp | 952,996 | $5.0M |
| affinity asset advisors, llc | 868,020 | $4.5M |
| millennium management llc | 862,303 | $4.5M |
| blackrock, inc. | 799,943 | $4.2M |
| hhlr advisors, ltd. | 724,800 | $3.8M |
| renaissance technologies llc | 625,469 | $3.3M |
| d. e. shaw & co., inc. | 411,570 | $2.2M |
| blue owl capital holdings lp | 333,877 | $1.7M |
Showing top 10 of 86 institutional holders of Sagimet Biosciences Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Sagimet Biosciences Inc.'s pipeline?
Sagimet Biosciences Inc. (SGMT) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sagimet Biosciences Inc.'s lead drug candidate?
Sagimet Biosciences Inc.'s most advanced tracked candidate is denifanstat (Phase 1) for Healthy; MASH; MASLD.
What is Sagimet Biosciences Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Sagimet Biosciences Inc. has approximately 35.6 months of cash runway.
What is Sagimet Biosciences Inc.'s market capitalization?
Sagimet Biosciences Inc.'s market capitalization is approximately $403.2M.
Who is the CEO of Sagimet Biosciences Inc.?
Mr. David A. Happel is the chief executive officer of Sagimet Biosciences Inc. (SGMT).
Get the full picture on Sagimet Biosciences Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.